GlassScriptPhysician profile
Tamera Andrews
NPI 1740281690
$1,181.17
in general payments reported to CMS, 2019-2025
19 companies · $647 in 2025
The $647 reported for 2025 was more than what 78% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $64.31 · 2023: $114 · 2024: $355 · 2025: $647.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,117.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $544.28 | 2022-2025 | |
| Axsome Therapeutics, INC. | $81.16 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $65.60 | 2023-2025 | Vaxelis, Gardasil 9, Vaxneuvance |
| Otsuka America Pharmaceutical, INC. | $56.06 | 2024 | Rexulti |
| Ironshore Pharmaceuticals INC. | $49.95 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $49.15 | 2024 | Bevespi Aerosphere |
| Amgen INC. | $43.33 | 2023-2025 | Repatha, Repatha |
| Exact Sciences Corporation | $40.73 | 2023-2024 | Cologuard Collection Kit |
| Dexcom, INC. | $35.88 | 2024-2025 | Dexcom G6 Transmitter |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.70 | 2024-2025 | Caplyta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.52 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $29.27 | 2025 | Trelegy Ellipta |
| Gilead Sciences, INC. | $24.33 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.41 | 2022 | |
| Alkermes, INC. | $16.53 | 2024 | Vivitrol |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $15.55 | 2023 | Seglentis, Livalo |
| Antares Pharma, INC. | $14.47 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.12 | 2024 | Xifaxan, Trulance |
| Lilly USA, LLC | $12.13 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamera Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.